Clinical Trial Update: Assessment of AI Program 'DRISTi' as a Screening Tool

View source ↗

Summary

A clinical trial update indicates Artelus AI's DRISTi program is being evaluated as a screening tool for diabetic retinopathy and the study is currently recruit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Retinopathy

Snippet

Sponsor: Artelus AI | Conditions: Diabetic Retinopathy (DR) | Status: RECRUITING